Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
STAR Protocols|January 17, 2025
Protocol for in vivo immune cell analysis in subcutaneous murine tumor models using advanced flow cytometryKatrine Ingelshed, Marit M Melssen, Diana SpiegelbergSurgical Oncology Clinics of North America|May 14, 2019
Vaccine Strategy in MelanomaMinyoung Kwak, Katie M Leick, Marit M Melssen, et al.Journal for Immunotherapy of Cancer|April 18, 2023
Barriers to immune cell infiltration in tumorsMarit M Melssen, Natasha D Sheybani, Katie M Leick, et al.Journal for Immunotherapy of Cancer|March 20, 2023
Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4<sup>+</sup> and CD8<sup>+</sup> T cells for immunotherapy of cancerMarit M Melssen, Caroline T Fisher, Craig L Slingluff, et al.Frontiers in Oncology|December 19, 2022
NK cells reduce anergic T cell development in early-stage tumors by promoting myeloid cell maturationRobin S Lindsay, Marit M Melssen, Katarzyna Stasiak, et al.Iscience|May 24, 2024
MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumorsKatrine Ingelshed, Marit M Melssen, Pavitra Kannan, et al.Annals of Surgery|August 20, 2019
The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and AngiogenesisKatie M Leick, Anthony B Rodriguez, Marit M Melssen, et al.Journal for Immunotherapy of Cancer|May 1, 2020
Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironmentKarlyn E Pollack, Max O Meneveau, Marit M Melssen, et al.Oncoimmunology|October 6, 2018
Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanomaMarit M Melssen, Walter Olson, Nolan A Wages, et al.Cancer Immunology, Immunotherapy : CII|January 17, 2021
Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trialsMarit M Melssen, Karlyn E Pollack, Max O Meneveau, et al.Pageof 2